In last trading session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) saw 0.41 million shares changing hands with its beta currently measuring -0.18. Company’s recent per share price level of $0.18 trading at $0.0 or 2.27% at ring of the bell on the day assigns it a market valuation of $8.82M. That closing price of BCLI’s stock is at a discount of -1822.22% from its 52-week high price of $3.46 and is indicating a premium of 27.78% from its 52-week low price of $0.13. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.04 million shares which gives us an average trading volume of 1.96 million if we extend that period to 3-months.
For Brainstorm Cell Therapeutics, Inc. (BCLI), analysts’ consensus is at an average recommendation of a Hold while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.14 in the current quarter.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Upright in the green during last session for gaining 2.27%, in the last five days BCLI remained trading in the green while hitting it’s week-highest on Tuesday, 11/14/23 when the stock touched $0.18 price level, adding 14.29% to its value on the day. Brainstorm Cell Therapeutics, Inc.’s shares saw a change of -89.02% in year-to-date performance and have moved 5.63% in past 5-day. Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) showed a performance of -8.30% in past 30-days. Number of shares sold short was 3.57 million shares which calculate 0.93 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $10.00 to the stock, which implies a rise of 98.2% to its current value. Analysts have been projecting $10.00 as a low price target for the stock while placing it at a high target of $10.00. It follows that stock’s current price would drop -5455.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -5455.56% for stock’s current value.
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Statistics highlight that Brainstorm Cell Therapeutics, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -93.48% of value to its shares in past 6 months, showing an annual growth rate of -6.06% while that of industry is 14.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 26.30% in the current quarter and calculating -15.40% decrease in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.66% during past 5 years.
Brainstorm Cell Therapeutics, Inc. is more likely to be releasing its next quarterly report on November 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s Major holders
Insiders are in possession of 19.17% of company’s total shares while institution are holding 13.43 percent of that, with stock having share float percentage of 16.61%. Investors also watch the number of corporate investors in a company very closely, which is 13.43% institutions for Brainstorm Cell Therapeutics, Inc. that are currently holding shares of the company. Vanguard Group Inc is the top institutional holder at BCLI for having 1.42 million shares of worth $2.93 million. And as of Jun 29, 2023, it was holding 3.16% of the company’s outstanding shares.
The second largest institutional holder is Sabby Management, LLC, which was holding about 1.27 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 2.82% of outstanding shares, having a total worth of $2.61 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 0.95 million shares of worth $1.96 million or 2.11% of the total outstanding shares. The later fund manager was in possession of 0.4 million shares on Jun 29, 2023, making its stake of worth around $0.83 million in the company or a holder of 0.89% of company’s stock.